Literature DB >> 36171370

The psychedelic escape from depression.

Michael Eisenstein.   

Abstract

Entities:  

Keywords:  Depression; Drug discovery; Psychiatric disorders; Psychology

Mesh：

Substances：

Year:  2022        PMID： 36171370     DOI： 10.1038/d41586-022-02872-9

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  7 in total

1.  Trial of Psilocybin versus Escitalopram for Depression.

Authors:  Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt
Journal:  N Engl J Med       Date:  2021-04-15       Impact factor: 91.245

2.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

Authors:  Charles S Grob; Alicia L Danforth; Gurpreet S Chopra; Marycie Hagerty; Charles R McKay; Adam L Halberstadt; George R Greer
Journal:  Arch Gen Psychiatry       Date:  2010-09-06

3.  Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.

Authors:  Ling-Xiao Shao; Clara Liao; Ian Gregg; Pasha A Davoudian; Neil K Savalia; Kristina Delagarza; Alex C Kwan
Journal:  Neuron       Date:  2021-07-05       Impact factor: 18.688

4.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

5.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

6.  Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Authors:  Natalie Gukasyan; Alan K Davis; Frederick S Barrett; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2022-02       Impact factor: 4.153

7.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Authors:  Alan K Davis; Frederick S Barrett; Darrick G May; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Patrick H Finan; Roland R Griffiths
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.